Company Profile

Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing novel therapeutics to treat and prevent viral diseases. Its lead product candidate, pomotrelvir, which targets the coronavirus disease (COVID-19). Pomotrelvir is in clinical development to treat COVID-19 in adult and pediatric patients. The Company, by leveraging its knowledge of structure-based drug design, reversible covalent chemistry and viral biology, it has discovered and is developing novel product candidates with low nanomolar potency against SARS-CoV-2 and activity against all known pathogenic human coronaviruses. Its lead product candidate, pomotrelvir, inhibits the main coronaviral cysteine protease (Mpro), a viral protein essential for replication of all known coronaviruses, including SARS-CoV-2. Inhibiting Mpro prevents the liberation and assembly of the viral replication complex, blocking replication before it begins.

Employees

Sector

Biotechnology & Medical Research

More about the company

23-09-05	Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from S&P TMI Index	CI
23-08-31	Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from NASDAQ Composite Index	CI
23-08-30	MediPacific, Inc. completed the acquisition of Pardes Biosciences, Inc. from a group of shareholders.	CI
23-08-28	Pardes Biosciences Receives Tender Offer for MediPacific Merger Deal	MT
23-08-04	Pardes Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-07-17	Pardes Biosciences Agrees to Be Acquired by MediPacific; Shares Rise	MT
23-06-23	Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from Russell 2500 Value Index	CI
23-06-23	Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from Russell Small Cap Comp Value Index	CI
23-06-23	Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from Russell 2000 Index	CI
23-06-23	Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from Russell 3000 Value Index	CI
23-06-23	Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from Russell Small Cap Completeness Index	CI
23-06-23	Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from Russell 2000 Value Index	CI
23-06-23	Pardes Biosciences, Inc.(NasdaqGM:PRDS) dropped from Russell 2000 Dynamic Index	CI

23-04-04	SVB Securities Downgrades Pardes Biosciences to Market Perform From Outperform, Lowers Price Target to $2 From $9	MT
23-04-03	Jefferies Downgrades Pardes Biosciences to Hold From Buy, Lowers Price Target to $1.25 From $10	MT
23-03-15	JMP Securities Adjusts Price Target on Pardes Biosciences to $5 From $9, Maintains Market Outperform Rating	MT
23-01-27	SVB Securities Adjusts Pardes Biosciences' Price Target to $9 From $12, Keeps Outperform Rating	MT
22-12-13	JMP Securities Starts Pardes Biosciences at Market Outperform With $9 Price Target	MT

23-08-31	Pardes Biosciences Announces Closing of Tender Offer	AQ
23-08-28	MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences	BU
23-08-17	MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares	BU
23-08-07	PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS	BU
23-07-21	PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS	BU

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/31/23	Uri Lopatin	Tender	Director	6,138,246	9.9458%
8/31/23	Laura Hamill	Issuer sale	Director	220,390	0.3571%
8/31/23	Deborah Autor	Issuer sale	Director	220,390	0.3571%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PARDES BIOSCIENCES, INC.	-.--%	+0.94%	-	-	131M
LONZA GROUP AG	+1.14%	+3.46%	+4.57%	+24.14%	50.5B
REVOLUTION MEDICINES, INC.	-1.36%	+3.15%	+479.46%	+614.84%	46.01B
BEONE MEDICINES AG	-2.04%	+2.82%	+18.13%	+91.23%	42.85B
IQVIA HOLDINGS INC.	+2.72%	+5.93%	+33.12%	+19.66%	41.03B
CELLTRION, INC.	0.00%	-3.91%	+17.87%	+47.98%	32.02B
MEDPACE HOLDINGS, INC.	+0.72%	+2.62%	+32.57%	+145.37%	16.98B
ASCENDIS PHARMA A/S	-1.85%	-0.25%	-	-	17.05B
EUROFINS SCIENTIFIC SE	+3.06%	+4.63%	+7.40%	+35.00%	14.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.50%	+2.49%	+83.90%	+46.53%	13.84B
Average	+0.29%	+2.01%	+84.63%	+128.09%	30.51B
Weighted average by Cap.	+0.18%	+2.37%	+104.14%	+152.88%

Pardes Biosciences, Inc. Stock

Stocks

PRDS

US69945Q1058

Biotechnology & Medical Research

Latest news : Pardes Biosciences, Inc.

Analysts' recommendations: Pardes Biosciences, Inc.

Press Releases: Pardes Biosciences, Inc.

News in other languages: Pardes Biosciences, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile